OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company focuses on leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. Its segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and its pharmaceutical research and development. The diagnostics segment primarily consists of point-of-care operations. Its pharmaceutical business features Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage three or four chronic kidney disease (CKD) and vitamin D insufficiency, and Somatrogon (hGH-CTP), a once-weekly human growth hormone injection. Its NGENLA (somatrogon-ghla), is a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older.
종목 코드 OPK
회사 이름OPKO Health Inc
상장일Nov 02, 1995
CEODr. Tony F. Cruz, Ph.D.
직원 수2997
유형Ordinary Share
회계 연도 종료Nov 02
주소- -
도시- -
증권 거래소NASDAQ Global Select Consolidated
국가- -
우편 번호- -
전화- -
웹사이트- -
종목 코드 OPK
상장일Nov 02, 1995
CEODr. Tony F. Cruz, Ph.D.
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음